|
1
|
Dupont AG, Gabriel DA and Cohen MG:
Antiplatelet therapies and the role of antiplatelet resistance in
acute coronary syndrome. Thromb Res. 124:6–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gurbel PA and Tantry US: Clopidogrel
resistance? Thromb Res. 120:311–321. 2007. View Article : Google Scholar
|
|
3
|
Yang R and Wu F: The progress of research
on clopidogrel resistance. Int J Intern Med. 36:428–431. 2009.(In
Chinese).
|
|
4
|
Ford NF: Clopidogrel resistance:
pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 49:506–512.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kolandaivelu K and Bhatt DL: Overcoming
‘resistance’ to antiplatelet therapy: targeting the issue of
nonadherence. Nat Rev Cardiol. 7:461–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holmes MV, Perel P, Shah T, Hingorani AD
and Casas JP: CYP2C19 genotype, clopidogrel metabolism, platelet
function and cardiovascular events: a systematic review and
meta-analysis. JAMA. 306:2704–2714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simon T, Verstuyft C, Mary-Krause M,
Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N
and Becquemont L; French Registry of Acute ST-Elevation and
Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.
Genetic determinants of response to clopidogrel and cardiovascular
events. N Engl J Med. 360:363–375. 2009. View Article : Google Scholar
|
|
8
|
Taubert D, von Beckerath N, Grimberg G, et
al: Impact of P-glycoprotein on clopidogrel absorption. Clin
Pharmacol Ther. 80:486–501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gros P, Ben Neriah YB, Croop JM and
Housman DE: Isolation and expression of a complementary DNA that
confers multidrug resistance. Nature. 323:728–731. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakaeda T, Nakamura T and Okumura K: MDR1
genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm
Bull. 25:1391–1400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mega JL, Close SL, Wiviott SD, Shen L,
Walker JR, Simon T, Antman EM, Braunwald E and Sabatine MS: Genetic
variants in ABCB1 and CYP2C19 and cardiovascular outcomes after
treatment with clopidogrel and prasugrel in the TRITON-TIMI 38
trial: a pharmacogenetic analysis. Lancet. 376:1312–1319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neurology Committee of the Chinese Medical
Association for cerebrovascular disease diagnosis and treatment
guidelines for ischemic stroke. Chinese diagnosis and treatment
guidelines for ischemic stroke 2010. Chin J Neurol. 43:146–153.
2010.
|
|
13
|
Adams HP Jr, Bendixen BH, Kappelle LJ,
Biller J, Love BB, Gordon DL and Marsh EE III: Classification of
subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke
Treatment. Stroke. 24:35–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mega JL, Close SL, Wiviott SD, et al:
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl
J Med. 360:354–362. 2009. View Article : Google Scholar
|
|
15
|
Sibbing D, Morath T, Stegherr J, Braun S,
Vogt W, Hadamitzky M, Schömig A, Kastrati A and von Beckerath N:
Impact of proton pump inhibitors on the antiplatelet effects of
clopidogrel. Thromb Haemost. 101:714–719. 2009.PubMed/NCBI
|
|
16
|
Montalescot G, Sideris G, Meuleman C, et
al: A randomized comparison of high clopidogrel loading doses in
patients with non-ST-segment elevation acute coronary syndromes:
the ALBION (Assessment of the Best Loading Dose of Clopidogrel to
Blunt Platelet Activation, Inflammation and Ongoing Necrosis)
trial. J Am Coll Cardiol. 48:931–938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lepäntalo A, Virtanen KS, Heikkilä J,
Wartiovaara U and Lassila R: Limited early antiplatelet effect of
300 mg clopidogrel in patients with aspirin therapy undergoing
percutaneous coronary interventions. Eur Heart J. 25:476–483. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hall HM, Banerjee S and McGuire DK:
Variability of clopidogrel response in patients with type 2
diabetes mellitus. Diab Vasc Dis Res. 8:245–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Angiolillo DJ and Suryadevara S: Aspirin
and clopidogrel: efficacy and resistance in diabetes mellitus. Best
Pract Res Clin Endocrinol Metab. 23:375–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Angiolillo DJ, Fernandez-Ortiz A, Bernardo
E, et al: Platelet function profiles in patients with type 2
diabetes and coronary artery disease on combined aspirin and
elopidogrel treatment. Diabetes. 54:2430–2435. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gurbel PA, Antonino MJ and Tantry US:
Recent developments in clopidogrel pharmacology and their relation
to clinical outcomes. Expert Opin Drug Metab Toxicol. 5:989–1004.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kubica A, Kozinski M, Grzesk M, et al:
Genetic determinants of platelet response to clopidogrel. J Thromb
Thrombolysis. 32:459–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Delaney JT, Ramirez1 AH, Bowton E, Pulley
JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H,
Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC
and Denny JC: Predicting clopidogrel response using DNA samples
linked to an electronic health record. Clin Pharmacol Ther.
91:257–263. 2012. View Article : Google Scholar
|
|
24
|
Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ and
Zou JJ: CYP2C19 polymorphism and antiplatelet effects of
clopidogrel in Chinese stroke patients. Pharmazie. 183–186.
2013.PubMed/NCBI
|
|
25
|
Nyírő G, Inczédy-Farkas G, Reményi V, et
al: The effect of the CYP 2C19*2 polymorphism on stroke care. Acta
Physiol Hung. 99:33–39. 2012. View Article : Google Scholar
|
|
26
|
Wallentin L, James S, Storey RF, Armstrong
M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH and
Becker RC; PLATO investigators. Effect of CYP2C19 and ABCB1 single
nucleotide polymorphisms on outcomes of treatment with ticagrelor
versusclopidogrel for acute coronary syndromes: a genetic substudy
of the PLATO trial. Lancet. 376:1320–1328. 2010. View Article : Google Scholar : PubMed/NCBI
|
